FDAnews
www.fdanews.com/articles/85203-corgentech-s-trial-of-algrx-4975-meets-primary-endpoint

CORGENTECH'S TRIAL OF ALGRX 4975 MEETS PRIMARY ENDPOINT

March 10, 2006

Corgentech has reported positive clinical data from a Phase II clinical trial showing that ALGRX 4975-one of three non-opioid pain management drug candidates the company is developing-demonstrated sustained, statistically significant pain relief over placebo in patients with tendonitis of the elbow.

The 45-patient study met its primary endpoint-response to ALGRX 4975 in treating pain induced by wrist dorsiflexion four weeks after patients were treated with a single injection of ALGRX 4975 or placebo. At week four, 64 percent of patients treated with ALGRX 4975 were considered "responders," versus 30 percent of patients treated with placebo. A responder was defined as having no or slight pain upon wrist dorsiflexion on a 0-4 scale. For patients treated with ALGRX 4975, a statistically significant improvement in the responder analysis was maintained eight weeks after treatment compared to placebo, and the trend for ALGRX 4975 patients to have lower pain scores was maintained from two to 12 weeks. Secondary endpoints also favored the ALGRX 4975-treated group. Additionally, ALGRX 4975 was well tolerated at all time points during the 24-week study.